Moreover, our findings reveal that in individuals suffering from type 2 diabetes and experiencing acute myocardial infarction, the utilization of SGLT2 inhibitors yielded favorable outcomes, manifesting in reduced inflammatory burden and diminished infarct sizes when compared to alternative oral anti-diabetic agents, irrespective of glucose control [36]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.